Electra Therapeutics, Inc. Form 424B4 — Sep 18, 2026
Electra Therapeutics priced its IPO at $15.00 per share, selling 23,333,334 shares for gross proceeds of $350.0 million (approximately $319.9 million net), with Nasdaq Global Select Market listing under the symbol ETRA and delivery expected on or about September 21, 2026. Jefferies, TD Cowen, Evercore ISI and Cantor are underwriting, with a 30-day option to purchase up to 3,500,000 additional shares.
Key figures
- Cash Position
- 97725000
- Gross Proceeds
- 350000010
- Offering Price
- 15
- Shares Offered
- 23333334
- Shares Outstanding
- 62766955
- Cash Runway
- into 2029
- Net Proceeds
- approximately $319.9 million ($368.7 million if greenshoe exercised in full)
- Greenshoe Shares
- 3500000
- Rd Expense H1 2026
- 41637000
- Reverse Split Ratio
- 1-for-1.5002 (effected September 10, 2026)
- Accumulated Deficit
- 221890000
- Pro Forma Cash And Securities
- 417575000
- Underwriting Discount Total
- 24500001
- Pre Offering Shares Outstanding
- 39433621
- Underwriting Discount Per Share
- 1.05
- Aggregate Preferred Financing Gross Proceeds
- 301400000
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.